Lyra Therapeutics, Inc. (NASDAQ: LYRA) Stock Competitors & Peer Comparison

Lyra Therapeutics, Inc. (NASDAQ: LYRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LYRA stands at 63K. In comparison, VRTX has a market cap of 140.1B. Regarding current trading prices, LYRA is priced at $0.00 on the NASDAQ, while VRTX trades at $538.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LYRA currently has a P/E ratio of -0.01, whereas VRTX's P/E ratio is 29.01. In terms of profitability, LYRA's ROE is +12.11%, compared to VRTX's ROE of +0.23%. Regarding short-term risk, LYRA is less volatile compared to VRTX. This indicates lower risk in terms of short-term price fluctuations for LYRA.Check VRTX's competition here

Lyra Therapeutics, Inc. (NASDAQ: LYRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LYRA stands at 63K. In comparison, REGN has a market cap of 86.6B. Regarding current trading prices, LYRA is priced at $0.00 on the NASDAQ, while REGN trades at $829.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LYRA currently has a P/E ratio of -0.01, whereas REGN's P/E ratio is 18.43. In terms of profitability, LYRA's ROE is +12.11%, compared to REGN's ROE of +0.14%. Regarding short-term risk, LYRA is less volatile compared to REGN. This indicates lower risk in terms of short-term price fluctuations for LYRA.Check REGN's competition here

Lyra Therapeutics, Inc. (NASDAQ: LYRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LYRA stands at 63K. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, LYRA is priced at $0.00 on the NASDAQ, while VRNA trades at $106.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LYRA currently has a P/E ratio of -0.01, whereas VRNA's P/E ratio is -102.80. In terms of profitability, LYRA's ROE is +12.11%, compared to VRNA's ROE of -0.02%. Regarding short-term risk, LYRA is similarly volatile compared to VRNA. This indicates similar risk in terms of short-term price fluctuations for LYRA.Check VRNA's competition here

Lyra Therapeutics, Inc. (NASDAQ: LYRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LYRA stands at 63K. In comparison, MRNA has a market cap of 69.2B. Regarding current trading prices, LYRA is priced at $0.00 on the NASDAQ, while MRNA trades at $134.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LYRA currently has a P/E ratio of -0.01, whereas MRNA's P/E ratio is -21.40. In terms of profitability, LYRA's ROE is +12.11%, compared to MRNA's ROE of -0.39%. Regarding short-term risk, LYRA is less volatile compared to MRNA. This indicates lower risk in terms of short-term price fluctuations for LYRA.Check MRNA's competition here

Lyra Therapeutics, Inc. (NASDAQ: LYRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LYRA stands at 63K. In comparison, ARGX has a market cap of 64.2B. Regarding current trading prices, LYRA is priced at $0.00 on the NASDAQ, while ARGX trades at $1,034.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LYRA currently has a P/E ratio of -0.01, whereas ARGX's P/E ratio is 93.22. In terms of profitability, LYRA's ROE is +12.11%, compared to ARGX's ROE of +0.32%. Regarding short-term risk, LYRA is less volatile compared to ARGX. This indicates lower risk in terms of short-term price fluctuations for LYRA.Check ARGX's competition here

Lyra Therapeutics, Inc. (NASDAQ: LYRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LYRA stands at 63K. In comparison, RVMDW has a market cap of 48.6B. Regarding current trading prices, LYRA is priced at $0.00 on the NASDAQ, while RVMDW trades at $12.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LYRA currently has a P/E ratio of -0.01, whereas RVMDW's P/E ratio is -1.72. In terms of profitability, LYRA's ROE is +12.11%, compared to RVMDW's ROE of -0.96%. Regarding short-term risk, LYRA is less volatile compared to RVMDW. This indicates lower risk in terms of short-term price fluctuations for LYRA.Check RVMDW's competition here

Lyra Therapeutics, Inc. (NASDAQ: LYRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LYRA stands at 63K. In comparison, RVMD has a market cap of 45.6B. Regarding current trading prices, LYRA is priced at $0.00 on the NASDAQ, while RVMD trades at $212.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LYRA currently has a P/E ratio of -0.01, whereas RVMD's P/E ratio is -24.34. In terms of profitability, LYRA's ROE is +12.11%, compared to RVMD's ROE of -0.96%. Regarding short-term risk, LYRA is less volatile compared to RVMD. This indicates lower risk in terms of short-term price fluctuations for LYRA.Check RVMD's competition here

Lyra Therapeutics, Inc. (NASDAQ: LYRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LYRA stands at 63K. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, LYRA is priced at $0.00 on the NASDAQ, while SGEN trades at $228.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LYRA currently has a P/E ratio of -0.01, whereas SGEN's P/E ratio is -57.19. In terms of profitability, LYRA's ROE is +12.11%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, LYRA is less volatile compared to SGEN. This indicates lower risk in terms of short-term price fluctuations for LYRA.Check SGEN's competition here

Lyra Therapeutics, Inc. (NASDAQ: LYRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LYRA stands at 63K. In comparison, ONC has a market cap of 40.3B. Regarding current trading prices, LYRA is priced at $0.00 on the NASDAQ, while ONC trades at $370.89.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LYRA currently has a P/E ratio of -0.01, whereas ONC's P/E ratio is 66.35. In terms of profitability, LYRA's ROE is +12.11%, compared to ONC's ROE of +0.14%. Regarding short-term risk, LYRA is less volatile compared to ONC. This indicates lower risk in terms of short-term price fluctuations for LYRA.Check ONC's competition here

Lyra Therapeutics, Inc. (NASDAQ: LYRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LYRA stands at 63K. In comparison, ALNY has a market cap of 32.5B. Regarding current trading prices, LYRA is priced at $0.00 on the NASDAQ, while ALNY trades at $229.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LYRA currently has a P/E ratio of -0.01, whereas ALNY's P/E ratio is 43.71. In terms of profitability, LYRA's ROE is +12.11%, compared to ALNY's ROE of +0.94%. Regarding short-term risk, LYRA is less volatile compared to ALNY. This indicates lower risk in terms of short-term price fluctuations for LYRA.Check ALNY's competition here

Lyra Therapeutics, Inc. (NASDAQ: LYRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LYRA stands at 63K. In comparison, BNTX has a market cap of 28.4B. Regarding current trading prices, LYRA is priced at $0.00 on the NASDAQ, while BNTX trades at $111.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LYRA currently has a P/E ratio of -0.01, whereas BNTX's P/E ratio is -20.47. In terms of profitability, LYRA's ROE is +12.11%, compared to BNTX's ROE of -0.09%. Regarding short-term risk, LYRA is less volatile compared to BNTX. This indicates lower risk in terms of short-term price fluctuations for LYRA.Check BNTX's competition here

Lyra Therapeutics, Inc. (NASDAQ: LYRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LYRA stands at 63K. In comparison, INSM has a market cap of 28.3B. Regarding current trading prices, LYRA is priced at $0.00 on the NASDAQ, while INSM trades at $125.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LYRA currently has a P/E ratio of -0.01, whereas INSM's P/E ratio is -28.59. In terms of profitability, LYRA's ROE is +12.11%, compared to INSM's ROE of -1.11%. Regarding short-term risk, LYRA is less volatile compared to INSM. This indicates lower risk in terms of short-term price fluctuations for LYRA.Check INSM's competition here

Lyra Therapeutics, Inc. (NASDAQ: LYRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LYRA stands at 63K. In comparison, ROIV has a market cap of 27B. Regarding current trading prices, LYRA is priced at $0.00 on the NASDAQ, while ROIV trades at $36.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LYRA currently has a P/E ratio of -0.01, whereas ROIV's P/E ratio is -35.58. In terms of profitability, LYRA's ROE is +12.11%, compared to ROIV's ROE of -0.06%. Regarding short-term risk, LYRA is less volatile compared to ROIV. This indicates lower risk in terms of short-term price fluctuations for LYRA.Check ROIV's competition here

Lyra Therapeutics, Inc. (NASDAQ: LYRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LYRA stands at 63K. In comparison, INCY has a market cap of 26B. Regarding current trading prices, LYRA is priced at $0.00 on the NASDAQ, while INCY trades at $127.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LYRA currently has a P/E ratio of -0.01, whereas INCY's P/E ratio is 17.27. In terms of profitability, LYRA's ROE is +12.11%, compared to INCY's ROE of +0.30%. Regarding short-term risk, LYRA is less volatile compared to INCY. This indicates lower risk in terms of short-term price fluctuations for LYRA.Check INCY's competition here

Lyra Therapeutics, Inc. (NASDAQ: LYRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LYRA stands at 63K. In comparison, UTHR has a market cap of 22.5B. Regarding current trading prices, LYRA is priced at $0.00 on the NASDAQ, while UTHR trades at $521.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LYRA currently has a P/E ratio of -0.01, whereas UTHR's P/E ratio is 18.93. In terms of profitability, LYRA's ROE is +12.11%, compared to UTHR's ROE of +0.20%. Regarding short-term risk, LYRA is less volatile compared to UTHR. This indicates lower risk in terms of short-term price fluctuations for LYRA.Check UTHR's competition here

Lyra Therapeutics, Inc. (NASDAQ: LYRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LYRA stands at 63K. In comparison, GMAB has a market cap of 20.9B. Regarding current trading prices, LYRA is priced at $0.00 on the NASDAQ, while GMAB trades at $33.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LYRA currently has a P/E ratio of -0.01, whereas GMAB's P/E ratio is 25.70. In terms of profitability, LYRA's ROE is +12.11%, compared to GMAB's ROE of +0.14%. Regarding short-term risk, LYRA is less volatile compared to GMAB. This indicates lower risk in terms of short-term price fluctuations for LYRA.Check GMAB's competition here

Lyra Therapeutics, Inc. (NASDAQ: LYRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LYRA stands at 63K. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, LYRA is priced at $0.00 on the NASDAQ, while BGNE trades at $184.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LYRA currently has a P/E ratio of -0.01, whereas BGNE's P/E ratio is -22.55. In terms of profitability, LYRA's ROE is +12.11%, compared to BGNE's ROE of +0.14%. Regarding short-term risk, LYRA is less volatile compared to BGNE. This indicates lower risk in terms of short-term price fluctuations for LYRA.Check BGNE's competition here

Lyra Therapeutics, Inc. (NASDAQ: LYRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LYRA stands at 63K. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, LYRA is priced at $0.00 on the NASDAQ, while DNA-WT trades at $0.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LYRA currently has a P/E ratio of -0.01, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, LYRA's ROE is +12.11%, compared to DNA-WT's ROE of -0.60%. Regarding short-term risk, LYRA is less volatile compared to DNA-WT. This indicates lower risk in terms of short-term price fluctuations for LYRA.Check DNA-WT's competition here

Lyra Therapeutics, Inc. (NASDAQ: LYRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LYRA stands at 63K. In comparison, BBIO has a market cap of 16.4B. Regarding current trading prices, LYRA is priced at $0.00 on the NASDAQ, while BBIO trades at $83.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LYRA currently has a P/E ratio of -0.01, whereas BBIO's P/E ratio is -22.45. In terms of profitability, LYRA's ROE is +12.11%, compared to BBIO's ROE of +0.32%. Regarding short-term risk, LYRA is less volatile compared to BBIO. This indicates lower risk in terms of short-term price fluctuations for LYRA.Check BBIO's competition here

Lyra Therapeutics, Inc. (NASDAQ: LYRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LYRA stands at 63K. In comparison, ASND has a market cap of 16.1B. Regarding current trading prices, LYRA is priced at $0.00 on the NASDAQ, while ASND trades at $256.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LYRA currently has a P/E ratio of -0.01, whereas ASND's P/E ratio is -107.28. In terms of profitability, LYRA's ROE is +12.11%, compared to ASND's ROE of +1.90%. Regarding short-term risk, LYRA is less volatile compared to ASND. This indicates lower risk in terms of short-term price fluctuations for LYRA.Check ASND's competition here

Lyra Therapeutics, Inc. (NASDAQ: LYRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LYRA stands at 63K. In comparison, JAZZ has a market cap of 15.8B. Regarding current trading prices, LYRA is priced at $0.00 on the NASDAQ, while JAZZ trades at $247.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LYRA currently has a P/E ratio of -0.01, whereas JAZZ's P/E ratio is 9.40. In terms of profitability, LYRA's ROE is +12.11%, compared to JAZZ's ROE of +0.21%. Regarding short-term risk, LYRA is less volatile compared to JAZZ. This indicates lower risk in terms of short-term price fluctuations for LYRA.Check JAZZ's competition here

Lyra Therapeutics, Inc. (NASDAQ: LYRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LYRA stands at 63K. In comparison, NBIX has a market cap of 15.6B. Regarding current trading prices, LYRA is priced at $0.00 on the NASDAQ, while NBIX trades at $153.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LYRA currently has a P/E ratio of -0.01, whereas NBIX's P/E ratio is 22.48. In terms of profitability, LYRA's ROE is +12.11%, compared to NBIX's ROE of +0.21%. Regarding short-term risk, LYRA is less volatile compared to NBIX. This indicates lower risk in terms of short-term price fluctuations for LYRA.Check NBIX's competition here

Lyra Therapeutics, Inc. (NASDAQ: LYRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LYRA stands at 63K. In comparison, EXEL has a market cap of 13.7B. Regarding current trading prices, LYRA is priced at $0.00 on the NASDAQ, while EXEL trades at $53.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LYRA currently has a P/E ratio of -0.01, whereas EXEL's P/E ratio is 15.54. In terms of profitability, LYRA's ROE is +12.11%, compared to EXEL's ROE of +0.42%. Regarding short-term risk, LYRA is less volatile compared to EXEL. This indicates lower risk in terms of short-term price fluctuations for LYRA.Check EXEL's competition here

Lyra Therapeutics, Inc. (NASDAQ: LYRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LYRA stands at 63K. In comparison, BMRN has a market cap of 13.4B. Regarding current trading prices, LYRA is priced at $0.00 on the NASDAQ, while BMRN trades at $67.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LYRA currently has a P/E ratio of -0.01, whereas BMRN's P/E ratio is 33.33. In terms of profitability, LYRA's ROE is +12.11%, compared to BMRN's ROE of +0.01%. Regarding short-term risk, LYRA is less volatile compared to BMRN. This indicates lower risk in terms of short-term price fluctuations for LYRA.Check BMRN's competition here

Lyra Therapeutics, Inc. (NASDAQ: LYRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LYRA stands at 63K. In comparison, HALO has a market cap of 12.8B. Regarding current trading prices, LYRA is priced at $0.00 on the NASDAQ, while HALO trades at $106.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LYRA currently has a P/E ratio of -0.01, whereas HALO's P/E ratio is 20.08. In terms of profitability, LYRA's ROE is +12.11%, compared to HALO's ROE of +1.81%. Regarding short-term risk, LYRA is less volatile compared to HALO. This indicates lower risk in terms of short-term price fluctuations for LYRA.Check HALO's competition here

Lyra Therapeutics, Inc. (NASDAQ: LYRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LYRA stands at 63K. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, LYRA is priced at $0.00 on the NASDAQ, while KRTX trades at $329.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LYRA currently has a P/E ratio of -0.01, whereas KRTX's P/E ratio is -28.09. In terms of profitability, LYRA's ROE is +12.11%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, LYRA is less volatile compared to KRTX. This indicates lower risk in terms of short-term price fluctuations for LYRA.Check KRTX's competition here

Lyra Therapeutics, Inc. (NASDAQ: LYRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LYRA stands at 63K. In comparison, ARWR has a market cap of 12.6B. Regarding current trading prices, LYRA is priced at $0.00 on the NASDAQ, while ARWR trades at $87.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LYRA currently has a P/E ratio of -0.01, whereas ARWR's P/E ratio is -39.74. In terms of profitability, LYRA's ROE is +12.11%, compared to ARWR's ROE of -0.61%. Regarding short-term risk, LYRA is less volatile compared to ARWR. This indicates lower risk in terms of short-term price fluctuations for LYRA.Check ARWR's competition here

Lyra Therapeutics, Inc. (NASDAQ: LYRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LYRA stands at 63K. In comparison, MDGL has a market cap of 12.5B. Regarding current trading prices, LYRA is priced at $0.00 on the NASDAQ, while MDGL trades at $526.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LYRA currently has a P/E ratio of -0.01, whereas MDGL's P/E ratio is -42.20. In terms of profitability, LYRA's ROE is +12.11%, compared to MDGL's ROE of -0.57%. Regarding short-term risk, LYRA is less volatile compared to MDGL. This indicates lower risk in terms of short-term price fluctuations for LYRA.Check MDGL's competition here

Lyra Therapeutics, Inc. (NASDAQ: LYRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LYRA stands at 63K. In comparison, TECH has a market cap of 11.3B. Regarding current trading prices, LYRA is priced at $0.00 on the NASDAQ, while TECH trades at $72.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LYRA currently has a P/E ratio of -0.01, whereas TECH's P/E ratio is 37.36. In terms of profitability, LYRA's ROE is +12.11%, compared to TECH's ROE of +0.09%. Regarding short-term risk, LYRA is less volatile compared to TECH. This indicates lower risk in terms of short-term price fluctuations for LYRA.Check TECH's competition here

Lyra Therapeutics, Inc. (NASDAQ: LYRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LYRA stands at 63K. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, LYRA is priced at $0.00 on the NASDAQ, while RNAM trades at $72.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LYRA currently has a P/E ratio of -0.01, whereas RNAM's P/E ratio is -17.39. In terms of profitability, LYRA's ROE is +12.11%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, LYRA is similarly volatile compared to RNAM. This indicates similar risk in terms of short-term price fluctuations for LYRA.Check RNAM's competition here

Lyra Therapeutics, Inc. (NASDAQ: LYRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LYRA stands at 63K. In comparison, AXSM has a market cap of 11.2B. Regarding current trading prices, LYRA is priced at $0.00 on the NASDAQ, while AXSM trades at $207.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LYRA currently has a P/E ratio of -0.01, whereas AXSM's P/E ratio is -56.97. In terms of profitability, LYRA's ROE is +12.11%, compared to AXSM's ROE of -2.56%. Regarding short-term risk, LYRA is less volatile compared to AXSM. This indicates lower risk in terms of short-term price fluctuations for LYRA.Check AXSM's competition here

Lyra Therapeutics, Inc. (NASDAQ: LYRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LYRA stands at 63K. In comparison, PRAX has a market cap of 10.8B. Regarding current trading prices, LYRA is priced at $0.00 on the NASDAQ, while PRAX trades at $369.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LYRA currently has a P/E ratio of -0.01, whereas PRAX's P/E ratio is -29.87. In terms of profitability, LYRA's ROE is +12.11%, compared to PRAX's ROE of -0.34%. Regarding short-term risk, LYRA is less volatile compared to PRAX. This indicates lower risk in terms of short-term price fluctuations for LYRA.Check PRAX's competition here

Lyra Therapeutics, Inc. (NASDAQ: LYRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LYRA stands at 63K. In comparison, KYMR has a market cap of 10.5B. Regarding current trading prices, LYRA is priced at $0.00 on the NASDAQ, while KYMR trades at $122.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LYRA currently has a P/E ratio of -0.01, whereas KYMR's P/E ratio is -39.78. In terms of profitability, LYRA's ROE is +12.11%, compared to KYMR's ROE of -0.22%. Regarding short-term risk, LYRA is less volatile compared to KYMR. This indicates lower risk in terms of short-term price fluctuations for LYRA.Check KYMR's competition here

Lyra Therapeutics, Inc. (NASDAQ: LYRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LYRA stands at 63K. In comparison, SMMT has a market cap of 10.4B. Regarding current trading prices, LYRA is priced at $0.00 on the NASDAQ, while SMMT trades at $12.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LYRA currently has a P/E ratio of -0.01, whereas SMMT's P/E ratio is -8.18. In terms of profitability, LYRA's ROE is +12.11%, compared to SMMT's ROE of -2.04%. Regarding short-term risk, LYRA is less volatile compared to SMMT. This indicates lower risk in terms of short-term price fluctuations for LYRA.Check SMMT's competition here

Lyra Therapeutics, Inc. (NASDAQ: LYRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LYRA stands at 63K. In comparison, KRYS has a market cap of 10.1B. Regarding current trading prices, LYRA is priced at $0.00 on the NASDAQ, while KRYS trades at $338.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LYRA currently has a P/E ratio of -0.01, whereas KRYS's P/E ratio is 43.03. In terms of profitability, LYRA's ROE is +12.11%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, LYRA is less volatile compared to KRYS. This indicates lower risk in terms of short-term price fluctuations for LYRA.Check KRYS's competition here

Lyra Therapeutics, Inc. (NASDAQ: LYRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LYRA stands at 63K. In comparison, IONS has a market cap of 10.1B. Regarding current trading prices, LYRA is priced at $0.00 on the NASDAQ, while IONS trades at $58.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LYRA currently has a P/E ratio of -0.01, whereas IONS's P/E ratio is -35.35. In terms of profitability, LYRA's ROE is +12.11%, compared to IONS's ROE of -1.11%. Regarding short-term risk, LYRA is less volatile compared to IONS. This indicates lower risk in terms of short-term price fluctuations for LYRA.Check IONS's competition here

Lyra Therapeutics, Inc. (NASDAQ: LYRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LYRA stands at 63K. In comparison, PTGX has a market cap of 10B. Regarding current trading prices, LYRA is priced at $0.00 on the NASDAQ, while PTGX trades at $149.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LYRA currently has a P/E ratio of -0.01, whereas PTGX's P/E ratio is 150.43. In terms of profitability, LYRA's ROE is +12.11%, compared to PTGX's ROE of +0.12%. Regarding short-term risk, LYRA is less volatile compared to PTGX. This indicates lower risk in terms of short-term price fluctuations for LYRA.Check PTGX's competition here

Lyra Therapeutics, Inc. (NASDAQ: LYRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LYRA stands at 63K. In comparison, CYTK has a market cap of 9.7B. Regarding current trading prices, LYRA is priced at $0.00 on the NASDAQ, while CYTK trades at $77.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LYRA currently has a P/E ratio of -0.01, whereas CYTK's P/E ratio is -10.77. In terms of profitability, LYRA's ROE is +12.11%, compared to CYTK's ROE of +1.64%. Regarding short-term risk, LYRA is less volatile compared to CYTK. This indicates lower risk in terms of short-term price fluctuations for LYRA.Check CYTK's competition here

Lyra Therapeutics, Inc. (NASDAQ: LYRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LYRA stands at 63K. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, LYRA is priced at $0.00 on the NASDAQ, while RXDX trades at $199.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LYRA currently has a P/E ratio of -0.01, whereas RXDX's P/E ratio is -56.47. In terms of profitability, LYRA's ROE is +12.11%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, LYRA is less volatile compared to RXDX. This indicates lower risk in terms of short-term price fluctuations for LYRA.Check RXDX's competition here

Lyra Therapeutics, Inc. (NASDAQ: LYRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LYRA stands at 63K. In comparison, SYRE has a market cap of 9.5B. Regarding current trading prices, LYRA is priced at $0.00 on the NASDAQ, while SYRE trades at $106.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LYRA currently has a P/E ratio of -0.01, whereas SYRE's P/E ratio is -55.86. In terms of profitability, LYRA's ROE is +12.11%, compared to SYRE's ROE of -0.24%. Regarding short-term risk, LYRA is less volatile compared to SYRE. This indicates lower risk in terms of short-term price fluctuations for LYRA.Check SYRE's competition here

Lyra Therapeutics, Inc. (NASDAQ: LYRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LYRA stands at 63K. In comparison, IMVT has a market cap of 9.3B. Regarding current trading prices, LYRA is priced at $0.00 on the NASDAQ, while IMVT trades at $44.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LYRA currently has a P/E ratio of -0.01, whereas IMVT's P/E ratio is -15.94. In terms of profitability, LYRA's ROE is +12.11%, compared to IMVT's ROE of -0.70%. Regarding short-term risk, LYRA is less volatile compared to IMVT. This indicates lower risk in terms of short-term price fluctuations for LYRA.Check IMVT's competition here

Lyra Therapeutics, Inc. (NASDAQ: LYRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LYRA stands at 63K. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, LYRA is priced at $0.00 on the NASDAQ, while NUVL trades at $123.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LYRA currently has a P/E ratio of -0.01, whereas NUVL's P/E ratio is -21.79. In terms of profitability, LYRA's ROE is +12.11%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, LYRA is similarly volatile compared to NUVL. This indicates similar risk in terms of short-term price fluctuations for LYRA.Check NUVL's competition here

Lyra Therapeutics, Inc. (NASDAQ: LYRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LYRA stands at 63K. In comparison, CRNX has a market cap of 9B. Regarding current trading prices, LYRA is priced at $0.00 on the NASDAQ, while CRNX trades at $84.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LYRA currently has a P/E ratio of -0.01, whereas CRNX's P/E ratio is -16.80. In terms of profitability, LYRA's ROE is +12.11%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, LYRA is less volatile compared to CRNX. This indicates lower risk in terms of short-term price fluctuations for LYRA.Check CRNX's competition here

Lyra Therapeutics, Inc. (NASDAQ: LYRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LYRA stands at 63K. In comparison, ABVX has a market cap of 8.9B. Regarding current trading prices, LYRA is priced at $0.00 on the NASDAQ, while ABVX trades at $117.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LYRA currently has a P/E ratio of -0.01, whereas ABVX's P/E ratio is -63.19. In terms of profitability, LYRA's ROE is +12.11%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, LYRA is less volatile compared to ABVX. This indicates lower risk in terms of short-term price fluctuations for LYRA.Check ABVX's competition here

Lyra Therapeutics, Inc. (NASDAQ: LYRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LYRA stands at 63K. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, LYRA is priced at $0.00 on the NASDAQ, while IMGN trades at $31.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LYRA currently has a P/E ratio of -0.01, whereas IMGN's P/E ratio is -111.55. In terms of profitability, LYRA's ROE is +12.11%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, LYRA is less volatile compared to IMGN. This indicates lower risk in terms of short-term price fluctuations for LYRA.Check IMGN's competition here

Lyra Therapeutics, Inc. (NASDAQ: LYRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LYRA stands at 63K. In comparison, PCVX has a market cap of 8.6B. Regarding current trading prices, LYRA is priced at $0.00 on the NASDAQ, while PCVX trades at $61.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LYRA currently has a P/E ratio of -0.01, whereas PCVX's P/E ratio is -7.84. In terms of profitability, LYRA's ROE is +12.11%, compared to PCVX's ROE of -0.38%. Regarding short-term risk, LYRA is less volatile compared to PCVX. This indicates lower risk in terms of short-term price fluctuations for LYRA.Check PCVX's competition here

Lyra Therapeutics, Inc. (NASDAQ: LYRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LYRA stands at 63K. In comparison, IBRX has a market cap of 8.5B. Regarding current trading prices, LYRA is priced at $0.00 on the NASDAQ, while IBRX trades at $7.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LYRA currently has a P/E ratio of -0.01, whereas IBRX's P/E ratio is -8.38. In terms of profitability, LYRA's ROE is +12.11%, compared to IBRX's ROE of +1.35%. Regarding short-term risk, LYRA is less volatile compared to IBRX. This indicates lower risk in terms of short-term price fluctuations for LYRA.Check IBRX's competition here

Lyra Therapeutics, Inc. (NASDAQ: LYRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LYRA stands at 63K. In comparison, ALKS has a market cap of 8.4B. Regarding current trading prices, LYRA is priced at $0.00 on the NASDAQ, while ALKS trades at $48.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LYRA currently has a P/E ratio of -0.01, whereas ALKS's P/E ratio is 52.82. In terms of profitability, LYRA's ROE is +12.11%, compared to ALKS's ROE of +0.04%. Regarding short-term risk, LYRA is less volatile compared to ALKS. This indicates lower risk in terms of short-term price fluctuations for LYRA.Check ALKS's competition here

Lyra Therapeutics, Inc. (NASDAQ: LYRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LYRA stands at 63K. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, LYRA is priced at $0.00 on the NASDAQ, while BPMC trades at $129.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LYRA currently has a P/E ratio of -0.01, whereas BPMC's P/E ratio is -51.58. In terms of profitability, LYRA's ROE is +12.11%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, LYRA is similarly volatile compared to BPMC. This indicates similar risk in terms of short-term price fluctuations for LYRA.Check BPMC's competition here

Lyra Therapeutics, Inc. (NASDAQ: LYRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LYRA stands at 63K. In comparison, APGE has a market cap of 8.3B. Regarding current trading prices, LYRA is priced at $0.00 on the NASDAQ, while APGE trades at $134.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LYRA currently has a P/E ratio of -0.01, whereas APGE's P/E ratio is -31.11. In terms of profitability, LYRA's ROE is +12.11%, compared to APGE's ROE of -0.30%. Regarding short-term risk, LYRA is less volatile compared to APGE. This indicates lower risk in terms of short-term price fluctuations for LYRA.Check APGE's competition here

Lyra Therapeutics, Inc. (NASDAQ: LYRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LYRA stands at 63K. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, LYRA is priced at $0.00 on the NASDAQ, while CERE trades at $44.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LYRA currently has a P/E ratio of -0.01, whereas CERE's P/E ratio is -16.47. In terms of profitability, LYRA's ROE is +12.11%, compared to CERE's ROE of -0.72%. Regarding short-term risk, LYRA is less volatile compared to CERE. This indicates lower risk in terms of short-term price fluctuations for LYRA.Check CERE's competition here

Lyra Therapeutics, Inc. (NASDAQ: LYRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LYRA stands at 63K. In comparison, RYTM has a market cap of 7.9B. Regarding current trading prices, LYRA is priced at $0.00 on the NASDAQ, while RYTM trades at $110.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LYRA currently has a P/E ratio of -0.01, whereas RYTM's P/E ratio is -37.21. In terms of profitability, LYRA's ROE is +12.11%, compared to RYTM's ROE of -0.80%. Regarding short-term risk, LYRA is less volatile compared to RYTM. This indicates lower risk in terms of short-term price fluctuations for LYRA.Check RYTM's competition here

Lyra Therapeutics, Inc. (NASDAQ: LYRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LYRA stands at 63K. In comparison, TGTX has a market cap of 7.9B. Regarding current trading prices, LYRA is priced at $0.00 on the NASDAQ, while TGTX trades at $50.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LYRA currently has a P/E ratio of -0.01, whereas TGTX's P/E ratio is 18.73. In terms of profitability, LYRA's ROE is +12.11%, compared to TGTX's ROE of +0.72%. Regarding short-term risk, LYRA is less volatile compared to TGTX. This indicates lower risk in terms of short-term price fluctuations for LYRA.Check TGTX's competition here

Lyra Therapeutics, Inc. (NASDAQ: LYRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LYRA stands at 63K. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, LYRA is priced at $0.00 on the NASDAQ, while MTSR trades at $70.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LYRA currently has a P/E ratio of -0.01, whereas MTSR's P/E ratio is -23.58. In terms of profitability, LYRA's ROE is +12.11%, compared to MTSR's ROE of -0.61%. Regarding short-term risk, LYRA is less volatile compared to MTSR. This indicates lower risk in terms of short-term price fluctuations for LYRA.Check MTSR's competition here

Lyra Therapeutics, Inc. (NASDAQ: LYRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LYRA stands at 63K. In comparison, CGON has a market cap of 7.1B. Regarding current trading prices, LYRA is priced at $0.00 on the NASDAQ, while CGON trades at $77.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LYRA currently has a P/E ratio of -0.01, whereas CGON's P/E ratio is -29.99. In terms of profitability, LYRA's ROE is +12.11%, compared to CGON's ROE of -0.25%. Regarding short-term risk, LYRA is less volatile compared to CGON. This indicates lower risk in terms of short-term price fluctuations for LYRA.Check CGON's competition here

Lyra Therapeutics, Inc. (NASDAQ: LYRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LYRA stands at 63K. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, LYRA is priced at $0.00 on the NASDAQ, while MRUS trades at $90.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LYRA currently has a P/E ratio of -0.01, whereas MRUS's P/E ratio is -17.05. In terms of profitability, LYRA's ROE is +12.11%, compared to MRUS's ROE of -0.46%. Regarding short-term risk, LYRA is similarly volatile compared to MRUS. This indicates similar risk in terms of short-term price fluctuations for LYRA.Check MRUS's competition here

Lyra Therapeutics, Inc. (NASDAQ: LYRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LYRA stands at 63K. In comparison, ORKA has a market cap of 6.8B. Regarding current trading prices, LYRA is priced at $0.00 on the NASDAQ, while ORKA trades at $105.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LYRA currently has a P/E ratio of -0.01, whereas ORKA's P/E ratio is -58.29. In terms of profitability, LYRA's ROE is +12.11%, compared to ORKA's ROE of -0.21%. Regarding short-term risk, LYRA is less volatile compared to ORKA. This indicates lower risk in terms of short-term price fluctuations for LYRA.Check ORKA's competition here

Lyra Therapeutics, Inc. (NASDAQ: LYRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LYRA stands at 63K. In comparison, SRRK has a market cap of 6.8B. Regarding current trading prices, LYRA is priced at $0.00 on the NASDAQ, while SRRK trades at $55.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LYRA currently has a P/E ratio of -0.01, whereas SRRK's P/E ratio is -16.38. In terms of profitability, LYRA's ROE is +12.11%, compared to SRRK's ROE of -1.60%. Regarding short-term risk, LYRA is less volatile compared to SRRK. This indicates lower risk in terms of short-term price fluctuations for LYRA.Check SRRK's competition here

Lyra Therapeutics, Inc. (NASDAQ: LYRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LYRA stands at 63K. In comparison, BLTE has a market cap of 6.8B. Regarding current trading prices, LYRA is priced at $0.00 on the NASDAQ, while BLTE trades at $163.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LYRA currently has a P/E ratio of -0.01, whereas BLTE's P/E ratio is -90.13. In terms of profitability, LYRA's ROE is +12.11%, compared to BLTE's ROE of -0.21%. Regarding short-term risk, LYRA is less volatile compared to BLTE. This indicates lower risk in terms of short-term price fluctuations for LYRA.Check BLTE's competition here

Lyra Therapeutics, Inc. (NASDAQ: LYRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LYRA stands at 63K. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, LYRA is priced at $0.00 on the NASDAQ, while ACLX trades at $115.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LYRA currently has a P/E ratio of -0.01, whereas ACLX's P/E ratio is -28.27. In terms of profitability, LYRA's ROE is +12.11%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, LYRA is less volatile compared to ACLX. This indicates lower risk in terms of short-term price fluctuations for LYRA.Check ACLX's competition here

Lyra Therapeutics, Inc. (NASDAQ: LYRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LYRA stands at 63K. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, LYRA is priced at $0.00 on the NASDAQ, while RETA trades at $172.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LYRA currently has a P/E ratio of -0.01, whereas RETA's P/E ratio is -66.29. In terms of profitability, LYRA's ROE is +12.11%, compared to RETA's ROE of +0.47%. Regarding short-term risk, LYRA is less volatile compared to RETA. This indicates lower risk in terms of short-term price fluctuations for LYRA.Check RETA's competition here

Lyra Therapeutics, Inc. (NASDAQ: LYRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LYRA stands at 63K. In comparison, CAI has a market cap of 6.4B. Regarding current trading prices, LYRA is priced at $0.00 on the NASDAQ, while CAI trades at $24.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LYRA currently has a P/E ratio of -0.01, whereas CAI's P/E ratio is 63.95. In terms of profitability, LYRA's ROE is +12.11%, compared to CAI's ROE of +0.19%. Regarding short-term risk, LYRA is less volatile compared to CAI. This indicates lower risk in terms of short-term price fluctuations for LYRA.Check CAI's competition here

Lyra Therapeutics, Inc. (NASDAQ: LYRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LYRA stands at 63K. In comparison, DNTH has a market cap of 6.4B. Regarding current trading prices, LYRA is priced at $0.00 on the NASDAQ, while DNTH trades at $109.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LYRA currently has a P/E ratio of -0.01, whereas DNTH's P/E ratio is -27.40. In terms of profitability, LYRA's ROE is +12.11%, compared to DNTH's ROE of -0.04%. Regarding short-term risk, LYRA is less volatile compared to DNTH. This indicates lower risk in terms of short-term price fluctuations for LYRA.Check DNTH's competition here

Lyra Therapeutics, Inc. (NASDAQ: LYRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LYRA stands at 63K. In comparison, COGT has a market cap of 6.3B. Regarding current trading prices, LYRA is priced at $0.00 on the NASDAQ, while COGT trades at $35.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LYRA currently has a P/E ratio of -0.01, whereas COGT's P/E ratio is -17.46. In terms of profitability, LYRA's ROE is +12.11%, compared to COGT's ROE of -0.73%. Regarding short-term risk, LYRA is less volatile compared to COGT. This indicates lower risk in terms of short-term price fluctuations for LYRA.Check COGT's competition here

Lyra Therapeutics, Inc. (NASDAQ: LYRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LYRA stands at 63K. In comparison, ERAS has a market cap of 6.3B. Regarding current trading prices, LYRA is priced at $0.00 on the NASDAQ, while ERAS trades at $17.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LYRA currently has a P/E ratio of -0.01, whereas ERAS's P/E ratio is -19.43. In terms of profitability, LYRA's ROE is +12.11%, compared to ERAS's ROE of -0.80%. Regarding short-term risk, LYRA is less volatile compared to ERAS. This indicates lower risk in terms of short-term price fluctuations for LYRA.Check ERAS's competition here

Lyra Therapeutics, Inc. (NASDAQ: LYRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LYRA stands at 63K. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, LYRA is priced at $0.00 on the NASDAQ, while CNTA trades at $40.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LYRA currently has a P/E ratio of -0.01, whereas CNTA's P/E ratio is -22.63. In terms of profitability, LYRA's ROE is +12.11%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, LYRA is similarly volatile compared to CNTA. This indicates similar risk in terms of short-term price fluctuations for LYRA.Check CNTA's competition here

Lyra Therapeutics, Inc. (NASDAQ: LYRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LYRA stands at 63K. In comparison, MIRM has a market cap of 6.2B. Regarding current trading prices, LYRA is priced at $0.00 on the NASDAQ, while MIRM trades at $97.89.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LYRA currently has a P/E ratio of -0.01, whereas MIRM's P/E ratio is -7.03. In terms of profitability, LYRA's ROE is +12.11%, compared to MIRM's ROE of -4.10%. Regarding short-term risk, LYRA is less volatile compared to MIRM. This indicates lower risk in terms of short-term price fluctuations for LYRA.Check MIRM's competition here

Lyra Therapeutics, Inc. (NASDAQ: LYRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LYRA stands at 63K. In comparison, PTCT has a market cap of 6.1B. Regarding current trading prices, LYRA is priced at $0.00 on the NASDAQ, while PTCT trades at $70.89.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LYRA currently has a P/E ratio of -0.01, whereas PTCT's P/E ratio is -31.62. In terms of profitability, LYRA's ROE is +12.11%, compared to PTCT's ROE of +0.22%. Regarding short-term risk, LYRA is less volatile compared to PTCT. This indicates lower risk in terms of short-term price fluctuations for LYRA.Check PTCT's competition here

Lyra Therapeutics, Inc. (NASDAQ: LYRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LYRA stands at 63K. In comparison, TVTX has a market cap of 6.1B. Regarding current trading prices, LYRA is priced at $0.00 on the NASDAQ, while TVTX trades at $64.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LYRA currently has a P/E ratio of -0.01, whereas TVTX's P/E ratio is -146.58. In terms of profitability, LYRA's ROE is +12.11%, compared to TVTX's ROE of -0.56%. Regarding short-term risk, LYRA is less volatile compared to TVTX. This indicates lower risk in terms of short-term price fluctuations for LYRA.Check TVTX's competition here

Lyra Therapeutics, Inc. (NASDAQ: LYRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LYRA stands at 63K. In comparison, DFTX has a market cap of 6.1B. Regarding current trading prices, LYRA is priced at $0.00 on the NASDAQ, while DFTX trades at $45.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LYRA currently has a P/E ratio of -0.01, whereas DFTX's P/E ratio is N/A. In terms of profitability, LYRA's ROE is +12.11%, compared to DFTX's ROE of -0.85%. Regarding short-term risk, LYRA is less volatile compared to DFTX. This indicates lower risk in terms of short-term price fluctuations for LYRA.Check DFTX's competition here

Lyra Therapeutics, Inc. (NASDAQ: LYRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LYRA stands at 63K. In comparison, XENE has a market cap of 6B. Regarding current trading prices, LYRA is priced at $0.00 on the NASDAQ, while XENE trades at $59.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LYRA currently has a P/E ratio of -0.01, whereas XENE's P/E ratio is -13.26. In terms of profitability, LYRA's ROE is +12.11%, compared to XENE's ROE of -0.44%. Regarding short-term risk, LYRA is less volatile compared to XENE. This indicates lower risk in terms of short-term price fluctuations for LYRA.Check XENE's competition here

Lyra Therapeutics, Inc. (NASDAQ: LYRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LYRA stands at 63K. In comparison, LGND has a market cap of 5.8B. Regarding current trading prices, LYRA is priced at $0.00 on the NASDAQ, while LGND trades at $287.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LYRA currently has a P/E ratio of -0.01, whereas LGND's P/E ratio is 31.91. In terms of profitability, LYRA's ROE is +12.11%, compared to LGND's ROE of +0.20%. Regarding short-term risk, LYRA is less volatile compared to LGND. This indicates lower risk in terms of short-term price fluctuations for LYRA.Check LGND's competition here

Lyra Therapeutics, Inc. (NASDAQ: LYRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LYRA stands at 63K. In comparison, CRSP has a market cap of 5.8B. Regarding current trading prices, LYRA is priced at $0.00 on the NASDAQ, while CRSP trades at $58.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LYRA currently has a P/E ratio of -0.01, whereas CRSP's P/E ratio is -12.57. In terms of profitability, LYRA's ROE is +12.11%, compared to CRSP's ROE of -0.24%. Regarding short-term risk, LYRA is less volatile compared to CRSP. This indicates lower risk in terms of short-term price fluctuations for LYRA.Check CRSP's competition here

Lyra Therapeutics, Inc. (NASDAQ: LYRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LYRA stands at 63K. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, LYRA is priced at $0.00 on the NASDAQ, while CDTX trades at $221.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LYRA currently has a P/E ratio of -0.01, whereas CDTX's P/E ratio is -19.77. In terms of profitability, LYRA's ROE is +12.11%, compared to CDTX's ROE of -0.37%. Regarding short-term risk, LYRA is similarly volatile compared to CDTX. This indicates similar risk in terms of short-term price fluctuations for LYRA.Check CDTX's competition here

Lyra Therapeutics, Inc. (NASDAQ: LYRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LYRA stands at 63K. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, LYRA is priced at $0.00 on the NASDAQ, while ABCM trades at $23.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LYRA currently has a P/E ratio of -0.01, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, LYRA's ROE is +12.11%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, LYRA is less volatile compared to ABCM. This indicates lower risk in terms of short-term price fluctuations for LYRA.Check ABCM's competition here

Lyra Therapeutics, Inc. (NASDAQ: LYRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LYRA stands at 63K. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, LYRA is priced at $0.00 on the NASDAQ, while ISEE trades at $39.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LYRA currently has a P/E ratio of -0.01, whereas ISEE's P/E ratio is -22.44. In terms of profitability, LYRA's ROE is +12.11%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, LYRA is less volatile compared to ISEE. This indicates lower risk in terms of short-term price fluctuations for LYRA.Check ISEE's competition here

Lyra Therapeutics, Inc. (NASDAQ: LYRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LYRA stands at 63K. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, LYRA is priced at $0.00 on the NASDAQ, while APLS trades at $41.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LYRA currently has a P/E ratio of -0.01, whereas APLS's P/E ratio is 38.35. In terms of profitability, LYRA's ROE is +12.11%, compared to APLS's ROE of +0.40%. Regarding short-term risk, LYRA is less volatile compared to APLS. This indicates lower risk in terms of short-term price fluctuations for LYRA.Check APLS's competition here

Lyra Therapeutics, Inc. (NASDAQ: LYRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LYRA stands at 63K. In comparison, ACAD has a market cap of 5.2B. Regarding current trading prices, LYRA is priced at $0.00 on the NASDAQ, while ACAD trades at $29.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LYRA currently has a P/E ratio of -0.01, whereas ACAD's P/E ratio is 13.61. In terms of profitability, LYRA's ROE is +12.11%, compared to ACAD's ROE of +0.32%. Regarding short-term risk, LYRA is less volatile compared to ACAD. This indicates lower risk in terms of short-term price fluctuations for LYRA.Check ACAD's competition here

Lyra Therapeutics, Inc. (NASDAQ: LYRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LYRA stands at 63K. In comparison, DYN has a market cap of 5B. Regarding current trading prices, LYRA is priced at $0.00 on the NASDAQ, while DYN trades at $26.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LYRA currently has a P/E ratio of -0.01, whereas DYN's P/E ratio is -8.32. In terms of profitability, LYRA's ROE is +12.11%, compared to DYN's ROE of -0.64%. Regarding short-term risk, LYRA is less volatile compared to DYN. This indicates lower risk in terms of short-term price fluctuations for LYRA.Check DYN's competition here

Lyra Therapeutics, Inc. (NASDAQ: LYRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LYRA stands at 63K. In comparison, EWTX has a market cap of 5B. Regarding current trading prices, LYRA is priced at $0.00 on the NASDAQ, while EWTX trades at $43.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LYRA currently has a P/E ratio of -0.01, whereas EWTX's P/E ratio is -25.12. In terms of profitability, LYRA's ROE is +12.11%, compared to EWTX's ROE of -0.39%. Regarding short-term risk, LYRA is less volatile compared to EWTX. This indicates lower risk in terms of short-term price fluctuations for LYRA.Check EWTX's competition here

Lyra Therapeutics, Inc. (NASDAQ: LYRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LYRA stands at 63K. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, LYRA is priced at $0.00 on the NASDAQ, while TERN trades at $52.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LYRA currently has a P/E ratio of -0.01, whereas TERN's P/E ratio is -51.41. In terms of profitability, LYRA's ROE is +12.11%, compared to TERN's ROE of -0.20%. Regarding short-term risk, LYRA is less volatile compared to TERN. This indicates lower risk in terms of short-term price fluctuations for LYRA.Check TERN's competition here

Lyra Therapeutics, Inc. (NASDAQ: LYRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LYRA stands at 63K. In comparison, MANE has a market cap of 4.6B. Regarding current trading prices, LYRA is priced at $0.00 on the NASDAQ, while MANE trades at $102.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LYRA currently has a P/E ratio of -0.01, whereas MANE's P/E ratio is -35.42. In terms of profitability, LYRA's ROE is +12.11%, compared to MANE's ROE of -0.29%. Regarding short-term risk, LYRA is less volatile compared to MANE. This indicates lower risk in terms of short-term price fluctuations for LYRA.Check MANE's competition here

Lyra Therapeutics, Inc. (NASDAQ: LYRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LYRA stands at 63K. In comparison, PBLS has a market cap of 4.6B. Regarding current trading prices, LYRA is priced at $0.00 on the NASDAQ, while PBLS trades at $39.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LYRA currently has a P/E ratio of -0.01, whereas PBLS's P/E ratio is -44.72. In terms of profitability, LYRA's ROE is +12.11%, compared to PBLS's ROE of -0.15%. Regarding short-term risk, LYRA is less volatile compared to PBLS. This indicates lower risk in terms of short-term price fluctuations for LYRA.Check PBLS's competition here

Lyra Therapeutics, Inc. (NASDAQ: LYRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LYRA stands at 63K. In comparison, CELC has a market cap of 4.6B. Regarding current trading prices, LYRA is priced at $0.00 on the NASDAQ, while CELC trades at $91.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LYRA currently has a P/E ratio of -0.01, whereas CELC's P/E ratio is -21.78. In terms of profitability, LYRA's ROE is +12.11%, compared to CELC's ROE of -3.51%. Regarding short-term risk, LYRA is less volatile compared to CELC. This indicates lower risk in terms of short-term price fluctuations for LYRA.Check CELC's competition here

Lyra Therapeutics, Inc. (NASDAQ: LYRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LYRA stands at 63K. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, LYRA is priced at $0.00 on the NASDAQ, while FOLD trades at $14.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LYRA currently has a P/E ratio of -0.01, whereas FOLD's P/E ratio is -161.00. In terms of profitability, LYRA's ROE is +12.11%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, LYRA is similarly volatile compared to FOLD. This indicates similar risk in terms of short-term price fluctuations for LYRA.Check FOLD's competition here

Lyra Therapeutics, Inc. (NASDAQ: LYRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LYRA stands at 63K. In comparison, RLAY has a market cap of 4.5B. Regarding current trading prices, LYRA is priced at $0.00 on the NASDAQ, while RLAY trades at $19.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LYRA currently has a P/E ratio of -0.01, whereas RLAY's P/E ratio is -13.21. In terms of profitability, LYRA's ROE is +12.11%, compared to RLAY's ROE of -0.42%. Regarding short-term risk, LYRA is less volatile compared to RLAY. This indicates lower risk in terms of short-term price fluctuations for LYRA.Check RLAY's competition here

Lyra Therapeutics, Inc. (NASDAQ: LYRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LYRA stands at 63K. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, LYRA is priced at $0.00 on the NASDAQ, while AKRO trades at $54.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LYRA currently has a P/E ratio of -0.01, whereas AKRO's P/E ratio is -14.57. In terms of profitability, LYRA's ROE is +12.11%, compared to AKRO's ROE of -0.22%. Regarding short-term risk, LYRA is less volatile compared to AKRO. This indicates lower risk in terms of short-term price fluctuations for LYRA.Check AKRO's competition here

Lyra Therapeutics, Inc. (NASDAQ: LYRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LYRA stands at 63K. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, LYRA is priced at $0.00 on the NASDAQ, while ALPN trades at $64.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LYRA currently has a P/E ratio of -0.01, whereas ALPN's P/E ratio is -101.52. In terms of profitability, LYRA's ROE is +12.11%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, LYRA is less volatile compared to ALPN. This indicates lower risk in terms of short-term price fluctuations for LYRA.Check ALPN's competition here

Lyra Therapeutics, Inc. (NASDAQ: LYRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LYRA stands at 63K. In comparison, AMLX has a market cap of 4.3B. Regarding current trading prices, LYRA is priced at $0.00 on the NASDAQ, while AMLX trades at $40.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LYRA currently has a P/E ratio of -0.01, whereas AMLX's P/E ratio is -25.73. In terms of profitability, LYRA's ROE is +12.11%, compared to AMLX's ROE of -0.53%. Regarding short-term risk, LYRA is less volatile compared to AMLX. This indicates lower risk in terms of short-term price fluctuations for LYRA.Check AMLX's competition here

Lyra Therapeutics, Inc. (NASDAQ: LYRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LYRA stands at 63K. In comparison, ELVN has a market cap of 4.2B. Regarding current trading prices, LYRA is priced at $0.00 on the NASDAQ, while ELVN trades at $58.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LYRA currently has a P/E ratio of -0.01, whereas ELVN's P/E ratio is -35.56. In terms of profitability, LYRA's ROE is +12.11%, compared to ELVN's ROE of -0.19%. Regarding short-term risk, LYRA is less volatile compared to ELVN. This indicates lower risk in terms of short-term price fluctuations for LYRA.Check ELVN's competition here

Lyra Therapeutics, Inc. (NASDAQ: LYRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LYRA stands at 63K. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, LYRA is priced at $0.00 on the NASDAQ, while OPT trades at $3.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LYRA currently has a P/E ratio of -0.01, whereas OPT's P/E ratio is -1.52. In terms of profitability, LYRA's ROE is +12.11%, compared to OPT's ROE of +1.18%. Regarding short-term risk, LYRA is similarly volatile compared to OPT. This indicates similar risk in terms of short-term price fluctuations for LYRA.Check OPT's competition here

Lyra Therapeutics, Inc. (NASDAQ: LYRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LYRA stands at 63K. In comparison, PRTC has a market cap of 4.2B. Regarding current trading prices, LYRA is priced at $0.00 on the NASDAQ, while PRTC trades at $17.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LYRA currently has a P/E ratio of -0.01, whereas PRTC's P/E ratio is -3.78. In terms of profitability, LYRA's ROE is +12.11%, compared to PRTC's ROE of -0.32%. Regarding short-term risk, LYRA is less volatile compared to PRTC. This indicates lower risk in terms of short-term price fluctuations for LYRA.Check PRTC's competition here

Lyra Therapeutics, Inc. (NASDAQ: LYRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LYRA stands at 63K. In comparison, VKTX has a market cap of 4.2B. Regarding current trading prices, LYRA is priced at $0.00 on the NASDAQ, while VKTX trades at $34.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LYRA currently has a P/E ratio of -0.01, whereas VKTX's P/E ratio is -8.69. In terms of profitability, LYRA's ROE is +12.11%, compared to VKTX's ROE of -0.95%. Regarding short-term risk, LYRA is less volatile compared to VKTX. This indicates lower risk in terms of short-term price fluctuations for LYRA.Check VKTX's competition here

Lyra Therapeutics, Inc. (NASDAQ: LYRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LYRA stands at 63K. In comparison, LEGN has a market cap of 4.2B. Regarding current trading prices, LYRA is priced at $0.00 on the NASDAQ, while LEGN trades at $21.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LYRA currently has a P/E ratio of -0.01, whereas LEGN's P/E ratio is -33.24. In terms of profitability, LYRA's ROE is +12.11%, compared to LEGN's ROE of -0.09%. Regarding short-term risk, LYRA is less volatile compared to LEGN. This indicates lower risk in terms of short-term price fluctuations for LYRA.Check LEGN's competition here

Lyra Therapeutics, Inc. (NASDAQ: LYRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LYRA stands at 63K. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, LYRA is priced at $0.00 on the NASDAQ, while MRTX trades at $58.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LYRA currently has a P/E ratio of -0.01, whereas MRTX's P/E ratio is -4.82. In terms of profitability, LYRA's ROE is +12.11%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, LYRA is less volatile compared to MRTX. This indicates lower risk in terms of short-term price fluctuations for LYRA.Check MRTX's competition here

Lyra Therapeutics, Inc. (NASDAQ: LYRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LYRA stands at 63K. In comparison, TLX has a market cap of 4.1B. Regarding current trading prices, LYRA is priced at $0.00 on the NASDAQ, while TLX trades at $12.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LYRA currently has a P/E ratio of -0.01, whereas TLX's P/E ratio is -658.70. In terms of profitability, LYRA's ROE is +12.11%, compared to TLX's ROE of -0.02%. Regarding short-term risk, LYRA is less volatile compared to TLX. This indicates lower risk in terms of short-term price fluctuations for LYRA.Check TLX's competition here

Lyra Therapeutics, Inc. (NASDAQ: LYRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LYRA stands at 63K. In comparison, TNGX has a market cap of 4.1B. Regarding current trading prices, LYRA is priced at $0.00 on the NASDAQ, while TNGX trades at $23.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LYRA currently has a P/E ratio of -0.01, whereas TNGX's P/E ratio is -30.36. In terms of profitability, LYRA's ROE is +12.11%, compared to TNGX's ROE of -0.26%. Regarding short-term risk, LYRA is less volatile compared to TNGX. This indicates lower risk in terms of short-term price fluctuations for LYRA.Check TNGX's competition here

Lyra Therapeutics, Inc. (NASDAQ: LYRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LYRA stands at 63K. In comparison, ADPT has a market cap of 4.1B. Regarding current trading prices, LYRA is priced at $0.00 on the NASDAQ, while ADPT trades at $25.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LYRA currently has a P/E ratio of -0.01, whereas ADPT's P/E ratio is -62.17. In terms of profitability, LYRA's ROE is +12.11%, compared to ADPT's ROE of -0.33%. Regarding short-term risk, LYRA is less volatile compared to ADPT. This indicates lower risk in terms of short-term price fluctuations for LYRA.Check ADPT's competition here

Lyra Therapeutics, Inc. (NASDAQ: LYRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LYRA stands at 63K. In comparison, DNLI has a market cap of 4.1B. Regarding current trading prices, LYRA is priced at $0.00 on the NASDAQ, while DNLI trades at $24.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LYRA currently has a P/E ratio of -0.01, whereas DNLI's P/E ratio is -8.92. In terms of profitability, LYRA's ROE is +12.11%, compared to DNLI's ROE of -0.55%. Regarding short-term risk, LYRA is less volatile compared to DNLI. This indicates lower risk in terms of short-term price fluctuations for LYRA.Check DNLI's competition here